nach oben

Erschienen in:

24.05.2016

Stem cells and diabetic cardiomyopathy: from pathology to therapy

verfasst von: Mingfei Liu, Han Chen, Jun Jiang, Zhaocai Zhang, Chen Wang, Na Zhang, Liang Dong, Xinyang Hu, Wei Zhu, Hong Yu, Jian’an Wang

Erschienen in: Heart Failure Reviews | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

The worldwide increase trend in the prevalence of diabetes has highlighted the need for increased research efforts into treatment options for both the disease itself and its associated complications. Diabetes has been widely recognized as a major risk factor for cardiovascular diseases, such as coronary heart disease and hypertension. Diabetic cardiomyopathy (DCM) is a main complication of diabetes, contributing to specific forms of heart failure independent from ischemia or hypertension. Without considerably effective approaches, a dire need exists to further explore the mechanisms and potential therapeutic strategies to prevent or reverse the progression of DCM. In the past decades, stem cell-based therapies have held promises to various diseases including DCM. The aim of the present review was to summarize the current literature with regard to the pathological changes of diabetic cardiomyopathy, endogenous stem cells in diabetes, and the exogenous stem cells transplantation for DCM. If the best use is made of the advantages of stem cells and their mechanism of action is explicitly explored, stem cell-based therapies could served as an important tool for the prevention and treatment of DCM patients.

American Diabetes A (2013) Diagnosis and classification of diabetes mellitus. Diabetes Care 36(Suppl 1):S67–S74. doi:10.2337/dc13-S067 CrossRef

Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87(1):4–14. doi:10.1016/j.diabres.2009.10.007 PubMedCrossRef

Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5):1047–1053PubMedCrossRef

Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M (2012) Prediabetes: a high-risk state for diabetes development. Lancet 379(9833):2279–2290. doi:10.1016/S0140-6736(12)60283-9 PubMedPubMedCentralCrossRef

Aronson D, Rayfield EJ, Chesebro JH (1997) Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med 126(4):296–306PubMedCrossRef

Rahman S, Rahman T, Ismail AA, Rashid AR (2007) Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diabetes Obes Metab 9(6):767–780. doi:10.1111/j.1463-1326.2006.00655.x PubMedCrossRef

Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, Tilbury RT, Davis BR, Holmes DR Jr (2004) Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the prevention of restenosis with tranilast and its outcomes (PRESTO) trial. Circulation 109(4):476–480. doi:10.1161/01.CIR.0000109693.64957.20 PubMedCrossRef

Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS, American Diabetes A, American Heart A, American College of Cardiology F (2010) Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 33(6):1395–1402. doi:10.2337/dc10-0555 PubMedPubMedCentralCrossRef

Chavali V, Tyagi SC, Mishra PK (2013) Predictors and prevention of diabetic cardiomyopathy. Diabetes Metab Syndr Obes Targets Ther 6:151–160. doi:10.2147/dmso.s30968

10.

Aurigemma GP, Zile MR, Gaasch WH (2006) Contractile behavior of the left ventricle in diastolic heart failure: with emphasis on regional systolic function. Circulation 113(2):296–304. doi:10.1161/CIRCULATIONAHA.104.481465 PubMedCrossRef

11.

Schannwell CM, Schneppenheim M, Perings S, Plehn G, Strauer BE (2002) Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology 98(1–2):33–39. doi:10.1159/000064682 PubMedCrossRef

12.

Diamant M, Lamb HJ, Groeneveld Y, Endert EL, Smit JW, Bax JJ, Romijn JA, de Roos A, Radder JK (2003) Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 42(2):328–335PubMedCrossRef

13.

Pham I, Cosson E, Nguyen MT, Banu I, Genevois I, Poignard P, Valensi P (2015) Evidence for a specific diabetic cardiomyopathy: an observational retrospective echocardiographic study in 656 asymptomatic type 2 diabetic patients. Int J Endocrinol 2015:743503. doi:10.1155/2015/743503 PubMedPubMedCentralCrossRef

14.

Muhammad Z, Hashmi A (2013) Frequency of diabetic cardiomyopathy among type-2 diabetics presenting as heart failure. J Coll Physicians Surg Pak 23(8):538–542PubMed

15.

Vinereanu D, Nicolaides E, Tweddel AC, Madler CF, Holst B, Boden LE, Cinteza M, Rees AE, Fraser AG (2003) Subclinical left ventricular dysfunction in asymptomatic patients with Type II diabetes mellitus, related to serum lipids and glycated haemoglobin. Clin Sci 105(5):591–599. doi:10.1042/CS20030168 PubMedCrossRef

16.

Basu R, Oudit GY, Wang X, Zhang L, Ussher JR, Lopaschuk GD, Kassiri Z (2009) Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function. Am J Physiol Heart Circ Physiol 297(6):H2096–H2108. doi:10.1152/ajpheart.00452.2009 PubMedCrossRef

17.

Saran V, Sharma V, Wambolt R, Yuen VG, Allard M, McNeill JH (2014) Combined metoprolol and ascorbic acid treatment prevents intrinsic damage to the heart during diabetic cardiomyopathy. Can J Physiol Pharmacol 92(10):827–837. doi:10.1139/cjpp-2014-0078 PubMedCrossRef

18.

Yu X, Tesiram YA, Towner RA, Abbott A, Patterson E, Huang S, Garrett MW, Chandrasekaran S, Matsuzaki S, Szweda LI, Gordon BE, Kem DC (2007) Early myocardial dysfunction in streptozotocin-induced diabetic mice: a study using in vivo magnetic resonance imaging (MRI). Cardiovasc Diabetol 6:6. doi:10.1186/1475-2840-6-6 PubMedPubMedCentralCrossRef

19.

Wichi R, Malfitano C, Rosa K, De Souza SB, Salemi V, Mostarda C, De Angelis K, Irigoyen MC (2007) Noninvasive and invasive evaluation of cardiac dysfunction in experimental diabetes in rodents. Cardiovasc Diabetol 6:14. doi:10.1186/1475-2840-6-14 PubMedPubMedCentralCrossRef

20.

Wood P, Piran S, Liu PP (2011) Diastolic heart failure: progress, treatment challenges, and prevention. Can J Cardiol 27(3):302–310. doi:10.1016/j.cjca.2011.02.008 PubMedCrossRef

21.

Galderisi M, Anderson KM, Wilson PW, Levy D (1991) Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 68(1):85–89PubMedCrossRef

22.

Bernardo BC, Weeks KL, Pretorius L, McMullen JR (2010) Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther 128(1):191–227. doi:10.1016/j.pharmthera.2010.04.005 PubMedCrossRef

23.

Ritchie RH, Irvine JC, Rosenkranz AC, Patel R, Wendt IR, Horowitz JD, Kemp-Harper BK (2009) Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO* and beyond. Pharmacol Ther 124(3):279–300. doi:10.1016/j.pharmthera.2009.08.001 PubMedCrossRef

24.

van Empel VP, De Windt LJ (2004) Myocyte hypertrophy and apoptosis: a balancing act. Cardiovasc Res 63(3):487–499. doi:10.1016/j.cardiores.2004.02.013 PubMedCrossRef

25.

Eguchi K, Boden-Albala B, Jin Z, Rundek T, Sacco RL, Homma S, Di Tullio MR (2008) Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol 101(12):1787–1791. doi:10.1016/j.amjcard.2008.02.082 PubMedPubMedCentralCrossRef

26.

Konstandin MH, Toko H, Gastelum GM, Quijada P, De La Torre A, Quintana M, Collins B, Din S, Avitabile D, Volkers M, Gude N, Fassler R, Sussman MA (2013) Fibronectin is essential for reparative cardiac progenitor cell response after myocardial infarction. Circ Res 113(2):115–125. doi:10.1161/circresaha.113.301152 PubMedCrossRef

27.

Gaetani R, Yin C, Srikumar N, Braden R, Doevendans PA, Sluijter JP, Christman KL (2015) Cardiac derived extracellular matrix enhances cardiogenic properties of human cardiac progenitor cells. Cell Transplant. doi:10.3727/096368915X689794 PubMed

28.

Zhang J, Klos M, Wilson GF, Herman AM, Lian X, Raval KK, Barron MR, Hou L, Soerens AG, Yu J, Palecek SP, Lyons GE, Thomson JA, Herron TJ, Jalife J, Kamp TJ (2012) Extracellular matrix promotes highly efficient cardiac differentiation of human pluripotent stem cells: the matrix sandwich method. Circ Res 111(9):1125–1136. doi:10.1161/CIRCRESAHA.112.273144 PubMedPubMedCentralCrossRef

29.

Westermann D, Rutschow S, Jager S, Linderer A, Anker S, Riad A, Unger T, Schultheiss HP, Pauschinger M, Tschope C (2007) Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 56(3):641–646. doi:10.2337/db06-1163 PubMedCrossRef

30.

Van Linthout S, Seeland U, Riad A, Eckhardt O, Hohl M, Dhayat N, Richter U, Fischer JW, Bohm M, Pauschinger M, Schultheiss HP, Tschope C (2008) Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol 103(4):319–327. doi:10.1007/s00395-008-0715-2 PubMedCrossRef

31.

Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, Ohmori K, Matsuo H (2000) Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation 101(8):899–907PubMedCrossRef

32.

Way KJ, Isshiki K, Suzuma K, Yokota T, Zvagelsky D, Schoen FJ, Sandusky GE, Pechous PA, Vlahos CJ, Wakasaki H, King GL (2002) Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes 51(9):2709–2718PubMedCrossRef

33.

D’Souza A, Howarth FC, Yanni J, Dobryznski H, Boyett MR, Adeghate E, Bidasee KR, Singh J (2011) Left ventricle structural remodelling in the prediabetic Goto-Kakizaki rat. Exp Physiol 96(9):875–888. doi:10.1113/expphysiol.2011.058271 PubMedCrossRef

34.

Begum N, Ragolia L (2000) High glucose and insulin inhibit VSMC MKP-1 expression by blocking iNOS via p38 MAPK activation. Am J Physiol Cell Physiol 278(1):C81–C91PubMed

35.

Tokudome T, Horio T, Yoshihara F, Suga S, Kawano Y, Kohno M, Kangawa K (2004) Direct effects of high glucose and insulin on protein synthesis in cultured cardiac myocytes and DNA and collagen synthesis in cardiac fibroblasts. Metab Clin Exp 53(6):710–715PubMedCrossRef

36.

Woodman OL, Malakul W, Cao AH, Xu Q, Ritchie RH (2008) Atrial natriuretic peptide prevents diabetes-induced endothelial dysfunction. Life Sci 82(15–16):847–854. doi:10.1016/j.lfs.2008.01.016 PubMedCrossRef

37.

Oltman CL, Richou LL, Davidson EP, Coppey LJ, Lund DD, Yorek MA (2006) Progression of coronary and mesenteric vascular dysfunction in Zucker obese and Zucker diabetic fatty rats. Am J Physiol Heart Circ Physiol 291(4):H1780–H1787. doi:10.1152/ajpheart.01297.2005 PubMedCrossRef

38.

Mather KJ, Lteif A, Steinberg HO, Baron AD (2004) Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes 53(8):2060–2066PubMedCrossRef

39.

Farhangkhoee H, Khan ZA, Kaur H, Xin X, Chen S, Chakrabarti S (2006) Vascular endothelial dysfunction in diabetic cardiomyopathy: pathogenesis and potential treatment targets. Pharmacol Ther 111(2):384–399. doi:10.1016/j.pharmthera.2005.10.008 PubMedCrossRef

40.

Irvine JC, Ritchie RH, Favaloro JL, Andrews KL, Widdop RE, Kemp-Harper BK (2008) Nitroxyl (HNO): the Cinderella of the nitric oxide story. Trends Pharmacol Sci 29(12):601–608. doi:10.1016/j.tips.2008.08.005 PubMedCrossRef

41.

Leo CH, Hart JL, Woodman OL (2011) Impairment of both nitric oxide-mediated and EDHF-type relaxation in small mesenteric arteries from rats with streptozotocin-induced diabetes. Br J Pharmacol 162(2):365–377. doi:10.1111/j.1476-5381.2010.01023.x PubMedPubMedCentralCrossRef

42.

Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, Munzel T (2001) Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88(2):E14–E22PubMedCrossRef

43.

Edgley AJ, Krum H, Kelly DJ (2012) Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-beta. Cardiovasc Ther 30(1):e30–e40. doi:10.1111/j.1755-5922.2010.00228.x PubMedCrossRef

44.

Chou E, Suzuma I, Way KJ, Opland D, Clermont AC, Naruse K, Suzuma K, Bowling NL, Vlahos CJ, Aiello LP, King GL (2002) Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 105(3):373–379PubMedCrossRef

45.

Yoon YS, Uchida S, Masuo O, Cejna M, Park JS, Gwon HC, Kirchmair R, Bahlman F, Walter D, Curry C, Hanley A, Isner JM, Losordo DW (2005) Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation 111(16):2073–2085. doi:10.1161/01.cir.0000162472.52990.36 PubMedCrossRef

46.

Zhang N, Xie X, Chen H, Chen H, Yu H, Wang JA (2014) Stem cell-based therapies for atherosclerosis: perspectives and ongoing controversies. Stem Cells Dev 23(15):1731–1740. doi:10.1089/scd.2014.0078 PubMedCrossRef

47.

Kojima H, Kim J, Chan L (2014) Emerging roles of hematopoietic cells in the pathobiology of diabetic complications. Trends Endocrinol Metab 25(4):178–187. doi:10.1016/j.tem.2014.01.002 PubMedPubMedCentralCrossRef

48.

Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284(5411):143–147PubMedCrossRef

49.

Mackay AM, Beck SC, Murphy JM, Barry FP, Chichester CO, Pittenger MF (1998) Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. Tissue Eng 4(4):415–428PubMedCrossRef

50.

Ferrari G, Cusella-De Angelis G, Coletta M, Paolucci E, Stornaiuolo A, Cossu G, Mavilio F (1998) Muscle regeneration by bone marrow-derived myogenic progenitors. Science 279(5356):1528–1530PubMedCrossRef

51.

De Ugarte DA, Morizono K, Elbarbary A, Alfonso Z, Zuk PA, Zhu M, Dragoo JL, Ashjian P, Thomas B, Benhaim P, Chen I, Fraser J, Hedrick MH (2003) Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs 174(3):101–109. doi:10.1159/000071150 PubMedCrossRef

52.

Tropel P, Platet N, Platel JC, Noel D, Albrieux M, Benabid AL, Berger F (2006) Functional neuronal differentiation of bone marrow-derived mesenchymal stem cells. Stem Cells (Dayton, Ohio) 24(12):2868–2876. doi:10.1634/stemcells.2005-0636 CrossRef

53.

Jin P, Zhang X, Wu Y, Li L, Yin Q, Zheng L, Zhang H, Sun C (2010) Streptozotocin-induced diabetic rat-derived bone marrow mesenchymal stem cells have impaired abilities in proliferation, paracrine, antiapoptosis, and myogenic differentiation. Transpl Proc 42(7):2745–2752. doi:10.1016/j.transproceed.2010.05.145 CrossRef

54.

Spinetti G, Cordella D, Fortunato O, Sangalli E, Losa S, Gotti A, Carnelli F, Rosa F, Riboldi S, Sessa F, Avolio E, Beltrami AP, Emanueli C, Madeddu P (2013) Global remodeling of the vascular stem cell niche in bone marrow of diabetic patients: implication of the microRNA-155/FOXO3a signaling pathway. Circ Res 112(3):510–522. doi:10.1161/circresaha.112.300598 PubMedCrossRef

55.

Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275(5302):964–967PubMedCrossRef

56.

Fadini GP, Losordo D, Dimmeler S (2012) Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res 110(4):624–637. doi:10.1161/CIRCRESAHA.111.243386 PubMedPubMedCentralCrossRef

57.

Fadini GP, Sartore S, Schiavon M, Albiero M, Baesso I, Cabrelle A, Agostini C, Avogaro A (2006) Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia-reperfusion injury in rats. Diabetologia 49(12):3075–3084. doi:10.1007/s00125-006-0401-6 PubMedCrossRef

58.

Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de Boer HC, Verhaar MC, Braam B, Rabelink TJ, van Zonneveld AJ (2004) Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 53(1):195–199PubMedCrossRef

59.

Gallagher KA, Liu ZJ, Xiao M, Chen H, Goldstein LJ, Buerk DG, Nedeau A, Thom SR, Velazquez OC (2007) Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Investig 117(5):1249–1259. doi:10.1172/JCI29710 PubMedPubMedCentralCrossRef

60.

Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348(7):593–600. doi:10.1056/NEJMoa022287 PubMedCrossRef

61.

Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, Gurtner GC (2002) Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106(22):2781–2786PubMedCrossRef

62.

Sibal L, Aldibbiat A, Agarwal SC, Mitchell G, Oates C, Razvi S, Weaver JU, Shaw JA, Home PD (2009) Circulating endothelial progenitor cells, endothelial function, carotid intima-media thickness and circulating markers of endothelial dysfunction in people with type 1 diabetes without macrovascular disease or microalbuminuria. Diabetologia 52(8):1464–1473. doi:10.1007/s00125-009-1401-0 PubMedCrossRef

63.

Egan CG, Lavery R, Caporali F, Fondelli C, Laghi-Pasini F, Dotta F, Sorrentino V (2008) Generalised reduction of putative endothelial progenitors and CXCR4-positive peripheral blood cells in type 2 diabetes. Diabetologia 51(7):1296–1305. doi:10.1007/s00125-008-0939-6 PubMedCrossRef

64.

Fadini GP, Miorin M, Facco M, Bonamico S, Baesso I, Grego F, Menegolo M, de Kreutzenberg SV, Tiengo A, Agostini C, Avogaro A (2005) Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 45(9):1449–1457. doi:10.1016/j.jacc.2004.11.067 PubMedCrossRef

65.

Hamed S, Brenner B, Abassi Z, Aharon A, Daoud D, Roguin A (2010) Hyperglycemia and oxidized-LDL exert a deleterious effect on endothelial progenitor cell migration in type 2 diabetes mellitus. Thromb Res 126(3):166–174. doi:10.1016/j.thromres.2010.03.002 PubMedCrossRef

66.

Fadini GP, Albiero M, Vigili de Kreutzenberg S, Boscaro E, Cappellari R, Marescotti M, Poncina N, Agostini C, Avogaro A (2013) Diabetes impairs stem cell and proangiogenic cell mobilization in humans. Diabetes Care 36(4):943–949. doi:10.2337/dc12-1084 PubMedPubMedCentralCrossRef

67.

She T, Wang X, Gan Y, Kuang D, Yue J, Ni J, Zhao X, Wang G (2012) Hyperglycemia suppresses cardiac stem cell homing to peri-infarcted myocardium via regulation of ERK1/2 and p38 MAPK activities. Int J Mol Med 30(6):1313–1320. doi:10.3892/ijmm.2012.1125 PubMed

68.

Rota M, LeCapitaine N, Hosoda T, Boni A, De Angelis A, Padin-Iruegas ME, Esposito G, Vitale S, Urbanek K, Casarsa C, Giorgio M, Luscher TF, Pelicci PG, Anversa P, Leri A, Kajstura J (2006) Diabetes promotes cardiac stem cell aging and heart failure, which are prevented by deletion of the p66shc gene. Circ Res 99(1):42–52. doi:10.1161/01.res.0000231289.63468.08 PubMedCrossRef

69.

Cramer C, Freisinger E, Jones RK, Slakey DP, Dupin CL, Newsome ER, Alt EU, Izadpanah R (2010) Persistent high glucose concentrations alter the regenerative potential of mesenchymal stem cells. Stem Cells Dev 19(12):1875–1884. doi:10.1089/scd.2010.0009 PubMedCrossRef

70.

Aggarwal S, Pittenger MF (2005) Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105(4):1815–1822. doi:10.1182/blood-2004-04-1559 PubMedCrossRef

71.

Fiorina P, Jurewicz M, Augello A, Vergani A, Dada S, La Rosa S, Selig M, Godwin J, Law K, Placidi C, Smith RN, Capella C, Rodig S, Adra CN, Atkinson M, Sayegh MH, Abdi R (2009) Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol 183(2):993–1004. doi:10.4049/jimmunol.0900803 PubMedPubMedCentralCrossRef

72.

Williams AR, Hare JM (2011) Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res 109(8):923–940. doi:10.1161/CIRCRESAHA.111.243147 PubMedPubMedCentralCrossRef

73.

Zhang N, Li J, Luo R, Jiang J, Wang JA (2008) Bone marrow mesenchymal stem cells induce angiogenesis and attenuate the remodeling of diabetic cardiomyopathy. Experimental and clinical endocrinology & diabetes: official journal. Ger Soc Endocrinol Ger Diabetes Assoc 116(2):104–111. doi:10.1055/s-2007-985154

74.

Li JH, Zhang N, Wang JA (2008) Improved anti-apoptotic and anti-remodeling potency of bone marrow mesenchymal stem cells by anoxic pre-conditioning in diabetic cardiomyopathy. J Endocrinol Invest 31(2):103–110. doi:10.1007/bf03345575 PubMedCrossRef

75.

Khan M, Ali F, Mohsin S, Akhtar S, Mehmood A, Choudhery MS, Khan SN, Riazuddin S (2013) Preconditioning diabetic mesenchymal stem cells with myogenic medium increases their ability to repair diabetic heart. Stem Cell Res Ther 4(3):58. doi:10.1186/scrt207 PubMedPubMedCentralCrossRef

76.

Khan M, Akhtar S, Mohsin S, N Khan S, Riazuddin S (2011) Growth factor preconditioning increases the function of diabetes-impaired mesenchymal stem cells. Stem Cells Dev 20(1):67–75. doi:10.1089/scd.2009.0397 PubMedCrossRef

77.

Calligaris SD, Conget P (2013) Intravenous administration of bone marrow-derived multipotent mesenchymal stromal cells has a neutral effect on obesity-induced diabetic cardiomyopathy. Biol Res 46(3):251–255. doi:10.4067/s0716-97602013000300005 PubMedCrossRef

78.

Volarevic V, Arsenijevic N, Lukic ML, Stojkovic M (2011) Concise review: mesenchymal stem cell treatment of the complications of diabetes mellitus. Stem Cells (Dayton, Ohio) 29(1):5–10. doi:10.1002/stem.556 CrossRef

79.

Shabbir A, Zisa D, Suzuki G, Lee T (2009) Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen. Am J Physiol Heart Circ Physiol 296(6):H1888–H1897. doi:10.1152/ajpheart.00186.2009 PubMedPubMedCentralCrossRef

80.

Cashman TJ, Gouon-Evans V, Costa KD (2013) Mesenchymal stem cells for cardiac therapy: practical challenges and potential mechanisms. Stem Cell Rev 9(3):254–265. doi:10.1007/s12015-012-9375-6 PubMedCrossRef

81.

Wang X, Zhao T, Huang W, Wang T, Qian J, Xu M, Kranias EG, Wang Y, Fan GC (2009) Hsp20-engineered mesenchymal stem cells are resistant to oxidative stress via enhanced activation of Akt and increased secretion of growth factors. Stem Cells (Dayton, Ohio) 27(12):3021–3031. doi:10.1002/stem.230

82.

Urbich C, Dimmeler S (2004) Endothelial progenitor cells: characterization and role in vascular biology. Circ Res 95(4):343–353. doi:10.1161/01.RES.0000137877.89448.78 PubMedCrossRef

83.

Asahara T, Kawamoto A, Masuda H (2011) Concise review: circulating endothelial progenitor cells for vascular medicine. Stem Cells 29(11):1650–1655. doi:10.1002/stem.745 PubMedCrossRef

84.

Jarajapu YP, Grant MB (2010) The promise of cell-based therapies for diabetic complications: challenges and solutions. Circ Res 106(5):854–869. doi:10.1161/CIRCRESAHA.109.213140 PubMedCrossRef

85.

Cheng Y, Guo S, Liu G, Feng Y, Yan B, Yu J, Feng K, Li Z (2012) Transplantation of bone marrow-derived endothelial progenitor cells attenuates myocardial interstitial fibrosis and cardiac dysfunction in streptozotocin-induced diabetic rats. Int J Mol Med 30(4):870–876. doi:10.3892/ijmm.2012.1083 PubMed

86.

Delucchi F, Berni R, Frati C, Cavalli S, Graiani G, Sala R, Chaponnier C, Gabbiani G, Calani L, Del Rio D, Bocchi L, Lagrasta C, Quaini F, Stilli D (2012) Resveratrol treatment reduces cardiac progenitor cell dysfunction and prevents morpho-functional ventricular remodeling in type-1 diabetic rats. PLoS ONE 7(6):e39836. doi:10.1371/journal.pone.0039836 PubMedPubMedCentralCrossRef

87.

Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4):663–676. doi:10.1016/j.cell.2006.07.024 PubMedCrossRef

88.

Pfannkuche K, Liang H, Hannes T, Xi J, Fatima A, Nguemo F, Matzkies M, Wernig M, Jaenisch R, Pillekamp F, Halbach M, Schunkert H, Saric T, Hescheler J, Reppel M (2009) Cardiac myocytes derived from murine reprogrammed fibroblasts: intact hormonal regulation, cardiac ion channel expression and development of contractility. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 24(1–2):73–86. doi:10.1159/000227815 CrossRef

89.

Yan B, Singla DK (2013) Transplanted induced pluripotent stem cells mitigate oxidative stress and improve cardiac function through the Akt cell survival pathway in diabetic cardiomyopathy. Mol Pharm 10(9):3425–3432. doi:10.1021/mp400258d PubMedCrossRef

90.

Neel S, Singla DK (2011) Induced pluripotent stem (iPS) cells inhibit apoptosis and fibrosis in streptozotocin-induced diabetic rats. Mol Pharm 8(6):2350–2357. doi:10.1021/mp2004675 PubMedCrossRef

91.

Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A, Cooper O, Mitalipova M, Isacson O, Jaenisch R (2009) Parkinson’s disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136(5):964–977. doi:10.1016/j.cell.2009.02.013 PubMedPubMedCentralCrossRef

92.

Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K (2009) Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature 458(7239):771–775. doi:10.1038/nature07864 PubMedPubMedCentralCrossRef

93.

Riggs JW, Barrilleaux BL, Varlakhanova N, Bush KM, Chan V, Knoepfler PS (2013) Induced pluripotency and oncogenic transformation are related processes. Stem Cells Dev 22(1):37–50. doi:10.1089/scd.2012.0375 PubMedCrossRef

94.

Ma T, Xie M, Laurent T, Ding S (2013) Progress in the reprogramming of somatic cells. Circ Res 112(3):562–574. doi:10.1161/CIRCRESAHA.111.249235 PubMedPubMedCentralCrossRef

95.

Stroedter D, Schmidt T, Bretzel RG, Federlin K (1995) Glucose metabolism and left ventricular dysfunction are normalized by insulin and islet transplantation in mild diabetes in the rat. Acta Diabetol 32(4):235–243PubMedCrossRef

96.

Laviola L, Belsanti G, Davalli AM, Napoli R, Perrini S, Weir GC, Giorgino R, Giorgino F (2001) Effects of streptozocin diabetes and diabetes treatment by islet transplantation on in vivo insulin signaling in rat heart. Diabetes 50(12):2709–2720PubMedCrossRef

97.

Sanada F, Kim J, Czarna A, Chan NYK, Signore S, Ogorek B, Isobe K, Wybieralska E, Borghetti G, Pesapane A, Sorrentino A, Mangano E, Cappetta D, Mangiaracina C, Ricciardi M, Cimini M, Ifedigbo E, Perrella MA, Goichberg P, Choi AM, Kajstura J, Hosoda T, Rota M, Anversa P, Leri A (2014) c-Kit-positive cardiac stem cells nested in hypoxic niches are activated by stem cell factor reversing the aging myopathy. Circ Res 114(1):41–55. doi:10.1161/Circresaha.114.302500 PubMedCrossRef

98.

Li Q, Li B, Wang X, Leri A, Jana KP, Liu Y, Kajstura J, Baserga R, Anversa P (1997) Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Investig 100(8):1991–1999. doi:10.1172/JCI119730 PubMedPubMedCentralCrossRef

99.

Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P (2001) Bone marrow cells regenerate infarcted myocardium. Nature 410(6829):701–705. doi:10.1038/35070587 PubMedCrossRef

100.

Li B, Li Q, Wang X, Jana KP, Redaelli G, Kajstura J, Anversa P (1997) Coronary constriction impairs cardiac function and induces myocardial damage and ventricular remodeling in mice. Am J Physiol 273(5 Pt 2):H2508–H2519PubMed

101.

Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD (2002) Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105(1):93–98. doi:10.1161/hc0102.101442 PubMedCrossRef

102.

Duan HF, Wu CT, Wu DL, Lu Y, Liu HJ, Ha XQ, Zhang QW, Wang H, Jia XX, Wang LS (2003) Treatment of myocardial ischemia with bone marrow-derived mesenchymal stem cells overexpressing hepatocyte growth factor. Mol Ther 8(3):467–474. doi:10.1016/S1525-0016(03)00186-2 PubMedCrossRef

103.

Bonaros N, Rauf R, Wolf D, Margreiter E, Tzankov A, Schlechta B, Kocher A, Ott H, Schachner T, Hering S, Bonatti J, Laufer G (2006) Combined transplantation of skeletal myoblasts and angiopoietic progenitor cells reduces infarct size and apoptosis and improves cardiac function in chronic ischemic heart failure. J Thorac Cardiovasc Surg 132(6):1321–1328. doi:10.1016/j.jtcvs.2006.07.023 PubMedCrossRef

104.

Memon IA, Sawa Y, Miyagawa S, Taketani S, Matsuda H (2005) Combined autologous cellular cardiomyoplasty with skeletal myoblasts and bone marrow cells in canine hearts for ischemic cardiomyopathy. J Thorac Cardiovasc Surg 130(3):646–653. doi:10.1016/j.jtcvs.2005.02.024 PubMedCrossRef

105.

Williams AR, Hatzistergos KE, Addicott B, McCall F, Carvalho D, Suncion V, Morales AR, Da Silva J, Sussman MA, Heldman AW, Hare JM (2013) Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. Circulation 127(2):213–223. doi:10.1161/circulationaha.112.131110 PubMedCrossRef

106.

Kishore R, Verma SK, Mackie AR, Vaughan EE, Abramova TV, Aiko I, Krishnamurthy P (2013) Bone marrow progenitor cell therapy-mediated paracrine regulation of cardiac miRNA-155 modulates fibrotic response in diabetic hearts. PLoS ONE 8(4):e60161. doi:10.1371/journal.pone.0060161 PubMedPubMedCentralCrossRef

107.

Wang Y, Xue M, Xuan YL, Hu HS, Cheng WJ, Suo F, Li XR, Yan SH, Wang LX (2013) Mesenchymal stem cell therapy improves diabetic cardiac autonomic neuropathy and decreases the inducibility of ventricular arrhythmias. Heart Lung Circ 22(12):1018–1025. doi:10.1016/j.hlc.2013.06.007 PubMedCrossRef

108.

Li L, Xia YF (2014) Study of adipose tissue-derived mesenchymal stem cells transplantation for rats with dilated cardiomyopathy. Ann Thorac Cardiovasc Surg 20(5):398–406. doi:10.5761/atcs.oa.13-00104 PubMedCrossRef

109.

Catelain C, Riveron S, Papadopoulos A, Mougenot N, Jacquet A, Vauchez K, Yada E, Puceat M, Fiszman M, Butler-Browne G, Bonne G, Vilquin JT (2013) Myoblasts and embryonic stem cells differentially engraft in a mouse model of genetic dilated cardiomyopathy. Mol Ther J Am Soc Gene Ther 21(5):1064–1075. doi:10.1038/mt.2013.15 CrossRef

110.

Assmus B, Zeiher AM (2013) Early cardiac retention of administered stem cells determines clinical efficacy of cell therapy in patients with dilated cardiomyopathy. Circ Res 112(1):6–8. doi:10.1161/CIRCRESAHA.112.300341 PubMedCrossRef

111.

Vrtovec B, Poglajen G, Lezaic L, Sever M, Domanovic D, Cernelc P, Socan A, Schrepfer S, Torre-Amione G, Haddad F, Wu JC (2013) Effects of intracoronary CD34 + stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up. Circ Res 112(1):165–173. doi:10.1161/CIRCRESAHA.112.276519 PubMedCrossRef

112.

Bartunek J, Behfar A, Dolatabadi D, Vanderheyden M, Ostojic M, Dens J, El Nakadi B, Banovic M, Beleslin B, Vrolix M, Legrand V, Vrints C, Vanoverschelde JL, Crespo-Diaz R, Homsy C, Tendera M, Waldman S, Wijns W, Terzic A (2013) Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol 61(23):2329–2338. doi:10.1016/j.jacc.2013.02.071 PubMedCrossRef

Titel: Stem cells and diabetic cardiomyopathy: from pathology to therapy
verfasst von: Mingfei Liu
Han Chen
Jun Jiang
Zhaocai Zhang
Chen Wang
Na Zhang
Liang Dong
Xinyang Hu
Wei Zhu
Hong Yu
Jian’an Wang
Publikationsdatum: 24.05.2016
Verlag: Springer US
Erschienen in: Heart Failure Reviews / Ausgabe 6/2016
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-016-9565-4

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

Zebrafish models of cardiovascular disease

Darwinian evolution and cardiovascular remodeling

Cognitive decline in heart failure

Recent advances in the noninvasive strategies of cardiac amyloidosis